CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients

Clinical and Experimental Immunology

Volumn 140, Issue 2, 2005, Pages 354-359

  Vander Cruyssen, Bert ^a   Peeters, H ^a   Hoffman, I E A ^a   Laukens, D ^b   Coucke, P ^a   Marichal, D ^a   Cuvelier, C ^a   Remaut, E ^b   Veys, E M ^a   Mielants, H ^a   De Vos, M ^a   De Keyser, F ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Antibodies; ASCA; CARD15; Caucasian; Crohn's disease

Indexed keywords

FUNGUS ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MARKER; SACCHAROMYCES CEREVISIAE ANTIBODY; SEROLOGICAL MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CARD15 GENE; CAUCASIAN; COMPOUND HETEROZYGOTE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILIAL DISEASE; FEMALE; GENE; GENETIC POLYMORPHISM; HETEROZYGOTE; HOMOZYGOTE; HUMAN; ILEUM DISEASE; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; INTESTINE RESECTION; INTESTINE STRICTURE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, FUNGAL; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC MARKERS; GENOTYPE; HETEROZYGOTE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LOGISTIC MODELS; MALE; MIDDLE AGED; NOD2 SIGNALING ADAPTOR PROTEIN; POLYMORPHISM, GENETIC; SACCHAROMYCES CEREVISIAE;

EID: 20244362211     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02759.x     Document Type: Article

References (43)

1. Hart AL, Stagg AJ, Frame M, Graffner H, Glise H, Falk P, Kamm MA. Review article, the role of the gut flora in health and disease, and its modification as therapy. Aliment Pharmacol Ther 2002; 16:1383-93.
2. Hampe J, Grebe J, Nikolaus S et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002; 359:1661-5.
3. Shanahan F. Crohn's disease. Lancet 2002; 359:62-9.
4. Elson CO. Genes, microbes, and T cells-new therapeutic targets in Crohn's disease. N Engl J Med 2002; 346:614-6.
5. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603.
6. Ogura Y, Bonen DK, Inohara N et al. A frame shift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603-6.
7. Abreu MT, Taylor KD, Lin YC et al. Mutations in NOD2 are associated with stricturing disease in patients with Crohn's disease. Gastroenterology 2002; 123:679-88.
8. Ahmad T, Armuzzi A, Bunce M et al. The molecular classification of th clinical manifestations of Crohn's disease. Gastroenterology 2002; 122:854-66.
9. Cuthbert AP, Fisher SA, Mirza MM et al. The contribution of NOD2gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002; 122:867-74.
10. Vermeire S, Wild G, Kocher K et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 2002; 71:74-83.
11. Heliö T, Halme L, Lappalainen M et al. CARD15/NOD2 gene variansts are associated with familially occuring and complicated forms of Crohn's disease. Gut 2003; 52:558-62.
12. Lesage S, Zouali H, Cezard JP et al. CARD15/NOD2 mutational analysis and genotype/phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002; 70:845-57.
13. Sendid B, Colombel JF, Jacquinot PM et al. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Laboratory Imm 1996; 3:219-26.
14. Main J, McKenzie H, Yeaman GR, Kerr MA, Robson D, Pennington CR, Parratt D. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. Br Med J 1988; 297:1105-6.
15. McKenzie H, Main J, Pennington CR, Parrat D. Antibody to selected srains of Saccharomyces cerevisiae (Baker's and brewer's yeast) and Candida albicans in Crohn's disease. Gut 1990; 310:536-8.
16. Quinton J, Sendid B, Reumaux D et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic auto-antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42:788-91.
17. Vermeire S, Joossens S, Peeters M et al. Comparative study of ASCA (anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 2001; 120:827-33.
18. Sandborn WJ, Loftus EV, Colombel JF et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2001; 7:192-201.
19. Mow WS, Vasiliauskas EA, Lin YC et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004; 126:414-24.
20. Vermeire S, Peeters M, Vlietinck R et al. Anti-Saccharomyces cerevisiae antibodies, phenotypes of IBD and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 2001; 7:8-15.
21. Peeters M, Joosens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic Value of anti-Saccharomyces cerevisiae and anti neutrophil cytoplasmic auto antibodies in inflammatory bowel disease. Am J Gastroenterol 2001; 96:730-4.
22. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000; 47:487-96.
23. Van Kemseke C, Belaiche J, Steeman C, Louis E. Negative association between smoking and anti-Saccharomyces cerevisiae antibodies in Crohn's disease. Acta Gastoenterol Belg 2003; 66:1-6.
24. Seibold F, Stich O, Hufnagl R, Kamil S, Sheurlen M. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a familial study. Scand J Gastroenterol 2001; 36:196-201.
25. Glas J, Torok HP, Vilsmaier F, Herbinger KH, Hoelscher M, Folwaczny C. Anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease and their first-degree relatives: potential clinical value. Digestion 2002; 66:173-7.
26. Lindberg E, Magnusson KE, Tysk C, Jarnerot G. Antibody (IgG, IgA and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease. Gut 1992; 33:909-13.
27. Sutton CL, Yang H, Li Z, Rotter JI, Targan S, Braun J. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut 2000;45:58-63.
28. Walker LJ, Aldhous MC, Drummond HE, Smith BR, Nimmo ER, Arnott ID, Satsangi J. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity, but not NOD2/CARD15 mutations. Clin Exp Immunol 2004; 135:490-6.
29. Linskens RK, Mallant-Hent RC, Murillo LS, von Blomberg BM, Alizadeh BZ, Peña AS. Genetic and serological markers to identify phenotypic subgroups in a Dutch Crohn's disease population. Dig Liver Dis 2004; 36:29-34.
30. Delamaire M, Timsit J, Caillat-Zucman S et al. HLA-associated heterogeneity of the humoral response to islet antigens in insulin-dependent diabetes. J Autoimmun 1995; 8:645-57.
31. Mäki M, Holm K, Lipsanen V, Hällström O, Viander M, Collin P, Savilahti E, Koskimies S. Serological markers and HLA genes among healthy first-degree relatives of patients with celiac disease. Lancet 1991; 91:1350-3.
32. Mattey DL, Dawes PT, Clarke S, Fisher J, Brownfield A, Thomson W, Haajeer A, Ollier W. Relationship among the HLA-DRB1 shared epitope, smoking and rheumatoid factor production in rheumatoid arthritis. Arthritis Rheum 2002; 47:403-7.
33. Lard LR, van Gaalen FA, Schonkeren JJ, Pieterman EJ et al. Association of the -2849 Interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis. Arthritis Rheum 2003; 48:1841-8.
34. Smolen JS, Klippel J, Penner E et al. HLA-DR antigens in systemic lupus erythematosus: association with specificity of autoantibody responses to nuclear antigens. Ann Rheum Dis 1987; 46:457-62.
35. Gottenberg JE, Busson M, Loiseau P, Cohen-Solal J, Lepage V, Charron D, Sibilla J, Mariette X. In primary Sjögren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum 2003; 48:2240-5.
36. Tsao BP. The genetics of Human lupus. In: Wallace DJ, Hannahs Hahn B, eds. Dubois' Lupus Eythematosus. Philadelphia: Lippincott Williams & Wilkins, 2002:101-2.
37. Gottenberg JE, Busson M, Loiseau P et al. Association of transforming growth factor β1 and tumour necrosis factor α polymorphisms with anti-SSB/La antibody secretion in patients with primary Sjögren's syndrome. Arthritis Rheum 2004; 50:570-80.
38. Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 2003; 124:521-36.
39. Inohara N, Ogura Y, Chen F, Muto F, Nunez G. Human Nod1 confers responsiveness to bacterial lipoppolysaccharides. J Biol Chem 2001; 276:2551-4.
40. Inohara N, Ogura Y, Fontalba A et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn's disease. J Biol Chem 2003; 278:5509-12.
41. Girardin S, Boneca I, Viala J et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide detection. J Biol Chem 2003; 278:8869-72.
42. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001; 276:4812-8.
43. Oshitani N, Hato F, Suzuki K et al. Cross-reactivity of yeast antigens in human colon and peripheral leukocytes. J Pathol 2003; 199:361-7.